Search

Your search keyword '"Nenov, D."' showing total 31 results
Start Over Author "Nenov, D." Publication Year Range Last 50 years
31 results on '"Nenov, D."'

4. Cardiopoietic cell therapy for advanced ischemic heart failure : results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Author

Bartunek, Jozef, Terzic, Andre, Davison, Beth A, Filippatos, Gerasimos S, Radovanovic, Slavica, Beleslin, Branko, Merkely, Bela, Musialek, Piotr, Wojakowski, Wojciech, Andreka, Peter, Horvath, Ivan G, Katz, Amos, Dolatabadi, Dariouch, El Nakadi, Badih, Arandjelovic, Aleksandra, Edes, Istvan, Seferovic, Petar M, Obradovic, Slobodan, Vanderheyden, Marc, Jagic, Nikola, Petrov, Ivo, Atar, Shaul, Halabi, Majdi, Gelev, Valeri L, Shochat, Michael K, Kasprzak, Jaroslaw D, Sanz Ruiz, Ricardo, Heyndrickx, Guy R, Nyolczas, Noémi, Legrand, Victor, Guédès, Antoine, Heyse, Alex, Moccetti, Tiziano, Fernandez Aviles, Francisco, Jimenez Quevedo, Pilar, Bayes Genis, Antoni, Hernandez Garcia, Jose Maria, Ribichini, Flavio, Gruchala, Marcin, Waldman, Scott A, Teerlink, John R, Gersh, Bernard J, Povsic, Thomas J, Henry, Timothy D, Metra, Marco, Hajjar, Roger J, Tendera, Michal, Behfar, Atta, Alexandre, Bertrand, Seron, Aymeric, Stough, Wendy Gattis, Sherman, Warren, Cotter, Gad, Wijns, W. i. l. l. i. a. m. Collaborators Clinical investigators, Dens, sites Belgium: Ziekenhuis Oost Limburg: J., Dupont, M., Mullens, W., Janssens, M., Dolatabadi, Hoˆpital Civil de Charleroi: D., De Bruyne, Y., Lalmand, J., Dubois, P., El Nakadi, B., Aminian, A., De Vuyst, E., Gurnet, P., Gujic, M., Blankoff, I., Guedes, CHU Mont Godinne UCL: A., Gabriel, L., Seldrum, S., Doyen, C., Andre´, M., Heyse, AZ Glorieux: A., Van Durme, F., Verschuere, J., Legrand, Domaine Universitaire du Sart Tilman: V., Gach, O., D’Orio, V., Davin, L., Lancellotti, P., Baudoux, E., Ancion, A., Dulgheru, R., Vanderheyden, OLV Ziekenhuis Aalst – Cardiologie: M., Bartunek, J., Wijns, W., Verstreken, S., Penicka, . M., Gelev, P. Meeus Bulgaria: Tokuda Hospital Sofia: V., Zheleva Kichukova, I., Parapunova, R., Melamed, R., Sardovski, S., Radev, O., Yordanov, A., Radinov, A., Nenov, D., Amine, I., Petrov, City Hospital Clinic Cardiology Center: I., Kichukov, K., Nikitasov, L., Stankov, Z., Stoyanov, H., Tasheva Dimitrova, I., Angelova, M., Dimitrov, E., Minchev, M., Garvanski, I., Botev, C., Polomski, P., Alexandrovska University Hospital, Vassilev, Sofia: D., Karamfiloff, K., Tarnovska Kadreva, R., Vladimirova, L., Dimitrov, G., Hadzhiev, E., Tzvetkova, G., Andreka, . M. Atanasova Hungary: Gottsegen Gyo¨ rgy Orszagos Kardiologiai Inte´zet: P., Fontos, G., Fabian, J., Csepregi, A., Uzonyi, G., Gelei, A., Edes, Debreceni Egyetem Orvos e´s Ege´szse´gtudomanyi Centrum Altalanos Orvostudomanyi Kar Kardiologia Inte´zet: I., Balogh, L., Vajda, G., Darago, A., Gergely, S., Fulop, T., Jenei, C., Horvath, Pe´csi Tudomanyegyetem Klinikai Ko¨zpont Szıvgyogyaszati Klinika: I., Magyari, B., Nagy, A., Cziraki, A., Faludi, R., Kittka, B., Alizadeh, H., Merkely, Semmelweis Egyetem Varosmajori Szıv e´s Ergyogyaszati Klinika: B., Geller, L., Farkas, P., Szombath, G., Foldes, G., Skopal, J., Kovacs, A., Kosztin, A., Gara, E., Sydo, N., Nyolczas, MH Ege´szse´gu¨gyi Ko¨zpont Kardiologiai Osztaly: N., Kerecsen, G., Korda, A., Kiss, . M., Borsanyi, T., Polgar, B., Muk, B., Sharif, Z. Bari Ireland: HRB Clinical Research Facility: F., Atar, Y. M. Smyth Israel:Western Galilee Hospital: S., Shturman, A., Akria, L., Kilimnik, M., Brezins, M., Halabi, Ziv Medical Center: M., Dally, N., Goldberg, A., Aehab, K., Rosenfeld, I., Levinas, T., Saleem, D., Katz, Barzilai Medical Center: A., Plaev, T., Drogenikov, T., Nemetz, A., Barshay, Y., Jafari, J., Orlov, I., Nazareth Hospital EMMS: M. Omory, N. Kogan Nielsen, Shochat, Hillel Yaffe Medical Center: M., Shotan, A., Frimerman, A., Meisel, S., Asif, A., Sofer, O., Blondheim, D. S., Vazan, A., Metra, L. Arobov Italy: A. O. Spedali Civili di Brescia: M., Bonadei, I., Inama, L., Chiari, E., Lombardi, C., Magatelli, M., Russo, D., Lazzarini, V., Carubelli, V., Vassanelli, AOUI Verona – Borgo Trento Hospital: C., Ribichini, Flavio Luciano, Bergamini, C., Krampera, Mauro, Cicoria, M. A., Zanolla, L., Dalla Mura, D., Gambaro, A., Rossi, A., Pesarini Poland: Jagiellonian University Department of Cardiac, G., Musialek, Vascular Diseases at John Paul II Hospital in Krakow: P., Mazurek, A., Drabik, L., Ka˛dzielski, A., Walter, Z., Dzieciuch Rojek, M., Rubis, P., Plazak, . W., Tekieli, L., Podolec, J., Orczyk, W., Sutor, U., Zmudka, K., Olszowska, M., Podolec, P., Gruchala, Uniwersyteckie Centrum Kliniczne: M., Ciecwierz, D., Mielczarek, M., Burakowski, S., Chmielecki, M., Zielinska, M., Frankiewicz, A., Wdowczyk, J., Stopczynska, I., Bellwon, J., Mosakowska, K., Nadolna, R., Wroblewska, J., Rozmyslowska, M., Rynkiewicz, M., Marciniak, I., Raczak, G., Tarnawska, M., Taszner, M., Kasprzak, Bieganski Hospital: J., Plewka, M., Fiutowska, D., Rechcinski, T., Lipiec, P., Sobczak, M., Weijner Mik, P., Wraga, M., Krecki, R., Markiewicz, M., Haval Qawoq, D., Wojakowski, Gornosla˛skie Centrum Medyczne Sla˛skie j. Akademii Medycznej: W., Ciosek, J., Dworowy, S., Gaszewska Zurek, E., Ochala, A., Cybulski, W., Jadczyk, T., Wanha, W., Parma, Z., Kozlowski, M., Dzierzak, M., Markiewicz Serbia: Clinical Hospital Center Zvezdara, M., Arandjelovic, Cardiology Clinic: A., Sekularac, N., Boljevic, D., Bogdanovic, A., Zivkovic, S., Cvetinovic, N., Loncar, G., Clinical Centre of Serbia, Beleslin, Cardiology Clinic: B., Nedeljkovic, M., Trifunovic, D., Giga, V., Banovic, M., Nedeljkovic, I., Stepanovic, J., Vukcevic, V., Djordjevic Dikic, A., Dobric, M., Obrenovic Kircanski, B., Seferovic, Cardiology Clinic: P., Orlic, D., Tesic, M., Petrovic, O., Milinkovic, I., Simeunovic, D., Jagic, Clinical Center of Kragujevac: N., Tasic, M., Nikolic, D., Miloradovic, V., Djurdjevic, P., Sreckovic, M., Zornic, N., Clinical Hospital Center Bezanijska Kosa, Radovanovic, Cardiology Department: S., Saric, J., Hinic, S., Djokovic, A., Ðordevic, S., Bisenic, V., Markovic, O., Stamenkovic, S., Malenkovic, V., Tresnjak, J., Misic, G., Cotra, D., Tomovic, L., Vuckovic, V., Clinic of Emergency Internal Medicine, Obradovic, Military Medical Academy: S., Jovic, Z., Vukotic, S., Markovic, D., Djenic, N., Ristic Andjelkov, A., Bayes Genis, D. Ljubinka Spain: Hospital Universitario Germans Trias I. Pujol: A., Rodriguez Leor, O., Labata, C., Vallejo, N., Ferrer, E., Batlle, M., Fernandez Aviles, Hospital General Universitario Gregorio Mara~non: F., Sanz Ruiz, R., Casado, A., Loughlin, G., Zatarain, E., Anguita, J., Ferna ndez Santos, M. E., Pascual, C., Bermejo, J., Hernandez Garcia, Hospital Clinico Universitario Virgen de la Victoria: J. M., Jimenez Navarro, M., Dominguez, A., Carrasco, F., Mu~noz, A., Garcia Pinilla, J. M., Ruiz, J., Queipo de Llano, M. P., Hernandez, A., Fernandez, A., Jimenez Quevedo, Hospital Clinico San Carlos: P., Guerra, R., Biagioni, C., Gonzalez, R. A., Gomez deDiego, J. J., Mansson Broberg, L. Perez de Isla Sweden: Karolinska University Hospital: A., Sylve´n, C., Leblanc, K., Winter, R., Blomberg, P., Gunyeli, E., Ruck, A., Silva, C., Fo¨rstedt Switzerland: CardioCentro Ticino, J., Moccetti, Switzerland: T., Rossi, M., Pasotti, E., Petrova, I., Crljenica, C., Monti, C., Murzilli, R., Su¨rder, D., Moccetti, M., Turchetto, L., Locicero, V., Chiumiento, L., Maspoli, S., Mombelli, M., Anesini, A., Biggiogero, M., Ponti, G., Camporini, C., Polledri, S., Hill, G. Dolci United Kingdom: Kings College Hospital: J., Plymen, C., Amin Youssef, G., Mcdonagh, T., Drasar, E., Mijovic, A., Jouhra, F., Mcloman, D., Dworakowski, R., Webb, I., Byrne, J., and Potter, V.

Subjects
0301 basic medicine, Male, Cardiopoiesis, Cardiovascular disease, Disease severity, Marker, Precision medicine, Regenerative medicine, Stem cell, Target population, Adult, Aged, Double-Blind Method, Female, Heart Failure, Humans, Mesenchymal Stem Cell Transplantation, Middle Aged, Myocardial Ischemia, Prospective Studies, Treatment Outcome, Young Adult, Cardiology and Cardiovascular Medicine, Cell- and Tissue-Based Therapy, mesenchymal stem-cells, 030204 cardiovascular system & hematology, Cardiorespiratory Medicine and Haematology, outcomes, Fast-Track Clinical Research, Sudden cardiac death, 0302 clinical medicine, Ischemia, cardiovascular disease, Clinical endpoint, target population, CHART Program, Ejection fraction, bone-marrow, Heart Failure/Cardiomyopathy, 3. Good health, Cohort, Cardiology, Fast Track, disease severity, delivery, medicine.medical_specialty, precision medicine, Clinical Sciences, regenerative medicine, 03 medical and health sciences, cardiopoiesis, Internal medicine, medicine, Adverse effect, marker, disease, business.industry, medicine.disease, mortality, Confidence interval, Clinical trial, stem cell, Editor's Choice, 030104 developmental biology, predictors, Cardiovascular System & Hematology, Heart failure, business
Abstract

Altres ajuts: This work was supported by Celyad, SA (Mont-Saint-Guibert, Belgium). Celyad has received research grants from the Walloon Region (Belgium, DG06 funding). Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort. This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein–Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann–Whitney estimator 0.54, 95% confidence interval [CI] 0.47–0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200–370 mL (60% of patients) (Mann–Whitney estimator 0.61, 95% CI 0.52–0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death. The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

Published
2017

8. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study.

Author

Elseviers, M. M., Waller, I., Nenov, D., Levora, J., Matousovic, K., Tanquerel, T., Pommer, W., Schwarz, A., Keller, E., Thieler, H., Köhler, H., Lemoniatou, H., Cresseri, D., Bonucchi, D., Fiocchi, O., Jordans, J., Franek, E., Silva, F. J., Fernandez Ruiz, E. J., and Morlans, M.

Abstract

It was found that in Belgium, renal imaging techniques, demonstrating a decreased renal mass of both kidneys combined with either bumpy contours or papillary calcifications, were the only methods to reliably diagnose analgesic nephropathy (AN) in patients with end-stage renal failure. However, these criteria were selected in an area with a high prevalence of this disease (15.6% of the dialysis population at December 1990). To evaluate the criteria selected to diagnose AN in populations with lower or unknown prevalences of AN, the Analgesic Nephropathy Network of Europe (ANNE) was formed, consisting of 23 dialysis units from 14 European countries and Brazil. During 1991–1992, 598 new patients with equivocal diagnosis of renal disease (excluding biopsy-proven glomerulonephritis, polycystic disease, diabetic nephropathy and other systemic diseases) and who began renal replacement therapy in the ANNE centres were evaluated by a short questionnaire and two renal imaging techniques: sonography and either tomography or computed tomography (CT) scan. A comparison of 82 abusers (daily use of analgesic mixtures for at least 5 years) and 495 controls corroborated the excellent diagnostic performance of the renal imaging techniques for AN. We recommend the use of these renal imaging criteria in all patients without a clear renal diagnosis in order to obtain a more reliable insight into the magnitude of the AN problem in different countries. [ABSTRACT FROM PUBLISHER]

Published
1995

9. Combined Treatment of Immune Nephropathies with Plasmapheresis and Immunosuppressants

Author

Nenov, D. and Metodiev, Kr.

Abstract

The treatment of patients with immune nephropathies is discussed: rapidly progressive nephritis, lupus nephropathy, Wegener granulomatosis, Goodpasture syndrome, Schonlein-Henoch nephritis. A combined treatment of plasmapheresis and imminosuppressants is applied. A definite result, specially with the cases of Wegener granulomatosis, is registered for certain number of the patients. Together with the usual tests: CIC, immunoglobulins, complement, etc. a method for controlling of the detoxic efficiency of the treatment is suggested. This is a biologic method-the level of paramecium caudatum in media from patients' plasma is registered in relation to time. After plasmapheresia the life of paramecium caudatum is considerably prolonged.

Published
1988
Full Text
View/download PDF

14. 20 years since the establishment of the BANTAO association (Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs).

Author

Polenakovic M, Nenov D, Basci A, Djukanovic L, Tsakiris D, Nesic V, Schiller A, Spasovski G, Klinkmann H, Vienken J, Falkenhagen D, and Ivanovich P

Subjects
Balkan Peninsula, Congresses as Topic organization & administration, History, 20th Century, History, 21st Century, Humans, Nephrology history, Societies, Medical history, Tissue and Organ Procurement history, Artificial Organs history, Cooperative Behavior, International Cooperation history, Nephrology organization & administration, Organ Transplantation history, Renal Dialysis history, Societies, Medical organization & administration, Tissue and Organ Procurement organization & administration
Abstract

The Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs (BANTAO) was born in Ohrid on October 9, 1993. The war in former Yugoslavia negatively affected the development of nephrology and also the connections among the nephrologists from the Balkans. However, there was willingness for further mutual collaboration between the nephrologists from the Balkans. The war in Yugoslavia created hate among people, between the newly established countries, and there were problems with the recognition of the names of the new countries, and so, the nephrologists decided to apply the ancient principle of using the names of the cities, instead of the countries, as the founders of the Association. The main goal of BANTAO is to promote scientific and technical cooperation in the fields of renal disease and artificial organs between the regions on the Balkan Peninsula and the world, to give an opportunity for exchange of experience and knowledge among the experts in the area and to engage in collaborative projects in order to demonstrate that cooperation is possible even on the turbulent Balkan Peninsula. The I BANTAO congress was held in Varna from September 22 to 24th, 1995 (President--D. Nenov, Varna). The II congress of BANTAO was held from September 6th to 10th, 1997 in Struga, (President--M. Polenakovic, Skopje). The III BANTAO congress was held in Belgrade from September 18th to 20th, 1998 (President--Lj. Djukanović, Belgrade). The IV congress of BANTAO was held in Izmir from 14th to 16th November 1999 (President--A. Akcicek, Izmir). The V Congress of BANTAO was held in Thessaloniki from September 30th to October 3rd, 2001 (President--P. Stathakis, Athens). The VI Congress of BANTAO was held for the second time in Varna from 6th to 9th October 2003 (President--D. Nenov, Varna). The VII congress of BANTAO was held from September 8th to 11th, 2005 in Ohrid, (President--M. Polenakovic, Skopje). The VIII BANTAO congress was held in Belgrade, 16-19 September 2007 (President--V. Nesic, Belgrade). The IX BANTAO congress was held in Antalya, 18-22 November 2009 (President--A. Basci, Izmir). The X BANTAO congress was held from 13 to 15 October 2011 in Chalkidiki (President--D. Tsakiris, Thessaloniki). The XI BANTAO congress is being held on 26-29 September 2013 in Timisoara (President--A. Schiller, Timisoara). At the VII BANTAO Congress for the first time a CME Course was organized by ERA/EDTA and ISN/COMGAN entitled "Frontiers in Nephrology" with seven distinguished speakers. Very important event in the existence of BANTAO is the appearance of the BANTAO journal in 2003. The BANTAO journal has been published biannually since 2003. In the past 10 years, 20 regular issues; 2 supplements (Antalia and Chalkidiki congresses) have been published. Editors of the journal were as follows: 2003-2005--D. Nenov, Editor; 2005-2009--A. Basci, Editor; 2009--Goce Spasovski, Editor. Until now 332 papers have been published. The BANTAO journal is on EBSCO, DOAJ, SCOPUS. After the First Congress of BANTAO, F. Valderrábano, chairman of the EDTA--ERA Registry, at that time, wrote in Nephrology Dialysis Transplantation (1996) 11:740: "Nephrologists of the Balkan countries meet across political frontiers and war fronts--an example to politicians!, Bantao: a new European Medical Association overcomes Political obstacles." Despite the difficulties imposed by major events, such as devastating wars and catastrophic earthquakes in many countries of the Balkan Peninsula BANTAO has made considerable progress. The BANTAO Congress was established as the major scientific and institutional forum for Balkan nephrologists, with its own journal, indicating our will to communicate, to collaborate, to get to know each other and to share our difficulties. Now, we expect further successful work of BANTAO.

Published
2013

15. [The effect of erythropoietin on megakaryocytopoiesis depressed by dialysable substances in experimental animals].

Author

Zorcheva R, Nenov D, and Diankov E

Subjects
Analysis of Variance, Animals, Depression, Chemical, Male, Rats, Rats, Wistar, Recombinant Proteins pharmacology, Stimulation, Chemical, Dialysis Solutions pharmacology, Erythropoietin pharmacology, Hematopoiesis drug effects, Megakaryocytes drug effects
Abstract

The aim of the study is to examine influence of r-Hu-Ero on megakaryocytopoiesis in rats with depressed by dialysable substances thrombocytopoiesis. Experimental animals are male Wistar rats, treated with bidestilled water, used dialysis solution and r-Hu-Ero. We investigate bone marrow of experimental rats. More expressed increase of megakaryocyte count "pro mile" in rats with depressed megakaryocytopoiesis, as well as influence on megakaryocyte maturation for shorter period of time, provide evidence to be accepted that megakaryocytopoiesis, depressed by dialysable substances is more sensitive to stimulating effect of r-Hu-Ero. The reason for this enhanced sensitivity at present appear unclear.

Published
1994

16. Low prekallikrein and high angiotensin-converting enzyme activity in patients with chronic renal failure on haemodialysis.

Author

Jankova T, Tchankova P, and Nenov D

Subjects
Adult, Aged, Amino Acid Sequence, Female, Humans, Hypertension blood, Hypertension etiology, Hypotension blood, Hypotension etiology, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Male, Middle Aged, Molecular Sequence Data, Oligopeptides chemistry, Prekallikrein deficiency, Renal Dialysis adverse effects, Substrate Specificity, Kidney Failure, Chronic blood, Peptidyl-Dipeptidase A blood, Prekallikrein metabolism
Abstract

Low prekallikrein is found in the plasma of patients with chronic renal failure (CRF) on intermittent haemodialysis (HD) (337 +/- 20.42 U/l before haemodialysis and 394.60 +/- 24.97 U/l after haemodialysis) versus normal data in the control group (755.80 +/- 24.37 U/l). Plasma activity of angiotensin converting enzyme (ACE) in patients with CRF is significantly decreased (14.91 +/- 0.57 U/l) in comparison to the control group (22.30 +/- 0.30 U/l). Intermittent haemodialysis increases plasma ACE activity. No differences exist after one haemodialysis procedure. There are no correlations between dialysis duration, plasma ACE activity, and prekallikrein. The ACE activity increase does not correlate with blood pressure but correlates significantly with the activation of complement and macrophage activity.

Published
1991

18. [External drainage of the thoracic duct with and without lymphosorption in the endotoxic phase of phalloid mushroom poisoning].

Author

Atanasov D, Nenov K, Nenov D, and Genova M

Subjects
Amanita, Child, Child, Preschool, Coma etiology, Coma therapy, Combined Modality Therapy, Drainage methods, Emergencies, Female, Humans, Mushroom Poisoning complications, Lymph, Mushroom Poisoning therapy, Sorption Detoxification methods, Thoracic Duct surgery
Abstract

For the first time in Bulgaria and maybe in the world is reported very good therapeutic effect of the application of external drainage of the thoracic duct with and without lymphosorption in two consecutive cases of phalloid mushroom poisoning. Concrete indications are suggested for application of the method in this type of poisoning - in the late endotoxic phase of the poisoning when all other methods have been used with no effect.

Published
1990

19. [Initial plasmapheresis treatment results in glomerulonephritis].

Author

Nenov D, Stanchev I, and Chankova P

Subjects
Adult, Chronic Disease, Evaluation Studies as Topic, Female, Humans, Lupus Erythematosus, Systemic therapy, Male, Glomerulonephritis therapy, Plasmapheresis
Abstract

The first results from the treatment of two cases with glomerulonephritis are reported--the first was an exacerbation of nephritis after intercurrent disease and second--with systemic lupus erythematosus, after plasmapheresis application as an active therapeutic method, in combination with corticosteroid cytostatic treatment. A reduction of the three immunoglobulins in plasma was found as a result from plasmapheresis and emergence of serum complement, together with clinical data for improvement of the patients. The prospects of plasmapheresis treatment of the active forms of glomerulonephritis are discussed.

Published
1981

21. Renal transplantation efficacy is dependent on pretransplantation immunologic monitoring.

Author

Drannik GN, Metodiev K, Nenov D, and Baran EY

Subjects
Adult, Biomarkers urine, Complement System Proteins analysis, Follow-Up Studies, Graft Survival, Humans, Macrophages immunology, Muramidase blood, Muramidase urine, Prognosis, Reference Values, Renal Dialysis, Rosette Formation, Tissue Donors, Transplantation, Homologous, Biomarkers blood, Graft Rejection, Kidney Transplantation, T-Lymphocytes immunology
Published
1989

22. [Therapeutic use of plasmapheresis in internal and skin diseases].

Author

Nenov D, Nenov K, Penev Z, and Chankova P

Subjects
Combined Modality Therapy, Humans, Immune System Diseases therapy, Kidney Diseases therapy, Multiple Myeloma therapy, Mushroom Poisoning therapy, Polyneuropathies therapy, Renal Dialysis, Internal Medicine, Plasmapheresis, Skin Diseases therapy
Published
1989

24. [Changes in the kallikrein-kinin system in chronic hemodialysis patients].

Author

Jankova T and Nenov D

Subjects
Adolescent, Adult, Humans, Kallikreins antagonists & inhibitors, Kidney Failure, Chronic therapy, Middle Aged, Protamines blood, Kallikreins blood, Kidney Failure, Chronic metabolism, Kinins metabolism, Prekallikrein blood, Renal Dialysis adverse effects
Abstract

The pre-kallikrein values, kallikrein inhibitors and protamine-splitting activity were determined in patients treated by means of chronic haemodialysis. Frequent use of dialysers leads to significant changes in the pre-kallikrein and kallikrein-inhibitor values. On the other hand the pre-kallikrein value remains unchanged after a single use of the capillary kidneys Hemoflow (Fresenius). A much smaller decrease in the kallikrein inhibitor value is observed than after frequent use of dialysers. In all the patients investigated the total protamine-splitting activity remained unchanged. Under these circumstances the inhibition capacity is probably sufficient to guarantee a control with respect to fibrinolysis, blood coagulation and the production of kinine.

Published
1982

25. [Hemoperfusion, a prospective therapeutic method].

Author

Nenov D and Dimitrov Kh

Subjects
Charcoal therapeutic use, Diuresis, Humans, Ion Exchange Resins therapeutic use, Perfusion instrumentation, Peritoneal Dialysis, Polystyrenes therapeutic use, Resins, Synthetic therapeutic use, Perfusion methods, Renal Dialysis methods
Published
1977

26. [Treatment of Wegener's granulomatosis using plasmapheresis].

Author

Nenov D, Stanchev I, Gurdevski M, Paskalev D, and Nenov K

Subjects
Adrenal Cortex Hormones therapeutic use, Adult, Combined Modality Therapy, Cyclophosphamide therapeutic use, Female, Granulomatosis with Polyangiitis pathology, Humans, Kidney pathology, Renal Dialysis, Granulomatosis with Polyangiitis therapy, Plasmapheresis
Abstract

A case with Wegener's granulomatosis in a young woman is described. The diagnosis was made after extirpation and histological investigation of granuloma tissue from the nasal concha and by needle renal biopsy. A successful treatment was carried out with plasmapheresis, hemodialysis and immune-suppressors, the acute paroxysm being coped as well as the developed acute renal insufficiency. After each plasmapheresis a considerable reduction of the circulating immune complexes was established. After a remission of 9 months the patient developed a stage of terminal chronic renal insufficiency and was subjected to chronic dialysis with good rehabilitation.

Published
1983

28. [Determination of the effectiveness of plasma exchange in kidney diseases by a biological test].

Author

Nenov K, Kovachev D, Kovacheva P, and Nenov D

Subjects
Animals, Biological Assay methods, Chronic Disease, Evaluation Studies as Topic, Humans, Kidney Diseases immunology, Paramecium immunology, Plasma immunology, Renal Dialysis, Kidney Diseases therapy, Plasma Exchange instrumentation, Plasma Exchange methods
Abstract

Plasma toxicity and plasma exchange efficacy were studied in two groups of patients: I gr.--8 patients with various degree of disturbed renal function who did not need hemodialysis treatment; II gr.--9 patients treated by periodic hemodialysis. A biologic toxicity test was used together with the clinical, immunologic and biochemical indices as a criterion for plasma exchange efficacy. The test gives direct information for the total plasma toxicity which is of great advantage and helps in the decision for another plasma exchange.

Published
1987

29. [Acute renal insufficiency in poisoning with cistol (carbon tetrachloride)].

Author

Nenov D and Angelov A

Subjects
Acute Kidney Injury therapy, Adult, Humans, Male, Middle Aged, Renal Dialysis, Acute Kidney Injury etiology, Carbon Tetrachloride Poisoning complications
Abstract

Three cases of acute intoxication with the preparation "Cistol", containing tetrachloro-methane were described, with the development of acute renal insufficiency, treated with hemodialysis. The attention of the physicians and the society is drawn to the risk of intoxication by that preparation. Early hemodialysis is recommended in case of such intoxications.

Published
1976

30. [Changes in the alkaline-acid status and some plasma electrolytes in chronic hemodialysis patients].

Author

Nenov D, Chankova P, and Dimitrov KH

Subjects
Acid-Base Imbalance blood, Adult, Female, Humans, Kidney Failure, Chronic blood, Male, Middle Aged, Acid-Base Equilibrium, Electrolytes blood, Kidneys, Artificial
Abstract

Prior to and post hemodialysis, a determination of plasma potassium, sodium, calcium, phosphorus and the indices of acid-base state is performed in 16 patients with chronic terminal renal insufficiency, with 560 hemodialyses, applied once or twice a week with deionized water and dialysis solution with 1, 5 mEq/1 potassium. Considerable hypopotassemia was established after hemodialysis--3, 3 mEq/1 and in 35% of the cases--hypopotassemia under 3.0 mEq/1. Metabolite alkalosis was established after dialysis: elevated pH in blood from 7,353 to 7,491; standard bicarbonates--from 21, 2 to 29, 1 m Eq/1; basis-excess: from (-3, 78) to (+5, 26) mEq/1; buffer bases: from 41, 3 to 51, 0 Eq/1, normalization of the elevated phosphorus in plasma from 7, 4 mg% to 4, 6 mg%. No significant changes in plasma sodium and potassium, as well as pCO2 were established after hemodialysis.

Published
1975

Catalog

Books, media, physical & digital resources
See catalog results